Alvotech Plans Multimillion Biosimilars Investment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Alvotech Plans Multimillion Biosimilars Investment
Alvotech plans investment in biosimilars portfolio and manufacturing facility.


Alvotech, a pharmaceutical company based in Reykjavik, Iceland, plans to invest $250 million to develop and manufacture biosimilar assets that include follow-on versions of monoclonal antibodies molecules, which will be brought to market by 2018.

Alvotech is an independent sister company of the multinational pharmaceuticals company, Alvogen, a multinational, privately owned pharmaceuticals company, focused on developing, manufacturing, and distributing generic, brand, over-the-counter brands (OTC), and biosimilar products. Through the Alvotech–Alvogen alliance, Alvogen will add key pipeline molecules to its existing biosimilar business. Alvogen currently markets biosimilars in selected regions through alliances with other firms, including Hospira and has several pending marketing authorizations worldwide.

Alvotech broke ground in November 2013 on a new 11,800-m2 development and manufacturing facility, where it will produce its own developed biosimilars, the first of which are already in advanced development stage. The site will provide Alvotech with a fully vertically integrated biologics manufacturing plant.

Source: Alvotech

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here